ROI in Pharmaceutical R&D: How to Halt the Decline
This report is designed to investigate recent years of performance of pharmaceutical and biopharmaceutical companies with respect to return on investment (ROI) in research and development (R&D), and to discuss ways that companies are trying to improve ROI through 2024. Investigation will include Country/Regional market trends with top areas of return, 2014-2024. This report also looks at which companies are already using artificial intelligence (AI) and machine learning (ML) to successfully compete globally.
- What are the major factors which have caused the decline in ROI in R&D for Pharma/Biotech?
- In what ways are new drug approvals affecting ROI?
- How can success rates in clinical development and testing be improved?
- How can tools such as Artificial Intelligence and Machine Learning, among others, decrease the costs of clinical trials?
- What is the digital transformation currently taking place, and how can companies deploy such tools?
The scope of this study begins with the challenges facing biotech and pharmaceutical companies today. It goes on to discuss regulatory approval processes in various countries, how these are changing, and the knock-on effects which the pharma/biotech companies will have to address. The report then reviews several key financial ratios, then discusses how to maximize clinical development success rate. We then go into how machine learning (ML) and artificial intelligence (AI), along with Big Data, are disrupting the pharma/biotech industry, in a positive way. The report then reviews the global markets for treatments for selected cancers, chronic diseases, cardiovascular disease, neurological diseases, infectious diseases and rare diseases. Chapter 15 discusses how companies need to deeply integrate ML, AI and Big Data into drug discovery and clinical testing—or risk falling behind the competition. The report wraps up with summaries of selected companies active in these spaces and beginning to utilize digital tools in R&D.
Valerie Kellogg, RRT, BA, MS/MBA is an experienced medical device and pharmaceutical professional with international market research experience. She has authored numerous reports on topics ranging from the treatment of obesity to ablation devices, from wound care to the treatment of chronic migraine. Her strong focus areas include oncology, treatment of chronic disease, the latest in surgical devices and analysis of potential acquisitions.